CAESAREA, Israel, Sept. 13, 2018 /PRNewswire/ -- XACT Robotics, a pioneer in robotic navigation and steering solutions for percutaneous image-guided procedures, announced today that it has received CE Mark approval for its robotics navigation and steering system for image-guided percutaneous procedures, such as ablations and biopsies.

The Company also announced that it has raised $5 million in round C investment. The funds will mainly be used for the launch and operation of seven Centers of Excellence in the US, Europe and Israel, where the Company expects that hundreds of clinical procedures will be conducted within the next 12 months with the XACT robotic navigation and steering system. The first Center of Excellence has already been launched earlier this year at the Hadassah Medical Center in Jerusalem, Israel, where the first cases were successfully completed as part of a clinical trial by Professor Nahum Goldberg, M.D., the Head of Interventional Oncology Unit and Director of the Applied Radiology Research Lab at Hadassah Medical Center, and the principal investigator in this study using XACT's novel system to target lesions.

The XACT robotics system is currently approved and being used for CT-guided percutaneous procedures in the abdomen. Later this year, the system's application is expected to be expanded for use in additional clinical centers and with other imaging modalities, such as Cone-Beam CT and Fluoroscopy, and for additional indications, including spinal and lung procedures.
"Currently, manual navigation of needles for biopsies and needle-based tools for procedures such as abscess drainage and tumor ablation, which are guided by imaging technologies, requires a high level of expertise and presents multiple challenges such as the need to construct a precise needle trajectory in 3D to avoid damaging critical intervening structures while simultaneously needing to compensate for target movement due to patient movements or breathing," commented Professor Goldberg. "XACT's solution has thus far demonstrated the potential to successfully addresses these challenges, by integrating robotic needle navigation and steering capabilities to achieve accurate access to a target within the body. We are very pleased with the results from the initial clinical procedures we performed as part of the trial, which further confirm the <1.5mm accuracy findings of the preclinical studies."

Cardiology Homepage